Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.

@article{Lack2011TargetingTB,
  title={Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.},
  author={Nathan A. Lack and Peter Axerio-Cilies and Peyman Tavassoli and Frank Q Han and Ka Hong Chan and Cl{\'e}mentine F{\'e}au and Eric Leblanc and Emma S. Tomlinson Guns and R. Kiplin Guy and Paul S. Rennie and Artem Cherkasov},
  journal={Journal of medicinal chemistry},
  year={2011},
  volume={54 24},
  pages={8563-73}
}
The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent… CONTINUE READING